{
  "id": 20784053,
  "title": "Two new 16-week tuberculosis regimens advance in clinical trial",
  "url": "https://urgent.news/2026/11/19/two-new-16-week-tuberculosis-regimens-advance-in-clinical-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T18:40:05.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-week-tuberculosis-regimens-advance-clinical.html"
  },
  "original_language": "en",
  "account": "Tuberculosis (TB) continues to be a leading cause of death globally, with the PARADIGM4TB trial advancing two new 16-week regimens in a clinical study. The 401-participant trial, led by UCL and Radboud University Medical Center, compared multiple regimens against the current standard-of-care. The most effective regimen, combining bedaquiline, pretomanid, moxifloxacin, and ganfeborole, showed promise in reducing sputum tuberculosis over 12 weeks and achieving favorable clinical outcomes by week 48. Another promising regimen featured bedaquiline, delamanid, moxifloxacin, and BTZ-043, but raised concerns about liver toxicity. The trial's success highlights the potential for shorter, more effective TB treatments, with the next stage aiming to shorten treatment durations while maintaining efficacy.",
  "summary": "Tuberculosis remains one of the world's deadliest infectious diseases, causing more than 1 million deaths each year. The development of new therapeutic regimens remains slow, costly and complex, while treatment remains lengthy and patients face the burden of side effects. Accelerating the identification of safer, shorter and more effective treatment options is essential to achieving global TB…",
  "key_points": [
    "Two new 16-week TB regimens advance in PARADIGM4TB trial",
    "Bedaquiline, pretomanid, moxifloxacin, and ganfeborole regimen shows promise",
    "Another regimen with bedaquiline, delamanid, moxifloxacin, BTZ-043 raises liver toxicity concerns"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}